Photo of Venkatraman Radhakrishnan from stjude.org
Oct 13, 2023, 17:15
Venkatraman Radhakrishnan: Inotuzumab take home points at SIOP 2023.
Venkatraman Radhakrishnan, Professor and Head of the Department of Medical Oncology at the Adyar Cancer Institute, shared on X/Twitter:
“Inotuzumab take home points at SIOP 2023:
- It is a bridge to transplant and Chimeric Antigen Receptor (CAR)-T cell therapy.
- Not effective in CNS.
- Risk of SOS.
- Can cause B cell aplasia so CAR-T might not work.
- CD22 negative cells can expand and relapse after intozumab.
- Inotuzumab before CAR-T doesn’t interfere with CAR-T.
